OFIX Stock Overview
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally.
No risks detected for OFIX from our risk checks.
Orthofix Medical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$27.18|
|52 Week High||US$43.30|
|52 Week Low||US$26.13|
|1 Month Change||-16.06%|
|3 Month Change||-12.94%|
|1 Year Change||-36.12%|
|3 Year Change||-47.96%|
|5 Year Change||-34.93%|
|Change since IPO||158.86%|
Recent News & Updates
Estimating The Fair Value Of Orthofix Medical Inc. (NASDAQ:OFIX)
How far off is Orthofix Medical Inc. ( NASDAQ:OFIX ) from its intrinsic value? Using the most recent financial data...
Companies Like Orthofix Medical (NASDAQ:OFIX) Can Afford To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...
|OFIX||US Medical Equipment||US Market|
Return vs Industry: OFIX underperformed the US Medical Equipment industry which returned -15.6% over the past year.
Return vs Market: OFIX underperformed the US Market which returned -10.4% over the past year.
|OFIX Average Weekly Movement||5.5%|
|Medical Equipment Industry Average Movement||10.4%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.7%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: OFIX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: OFIX's weekly volatility (6%) has been stable over the past year.
About the Company
Orthofix Medical Inc. operates as a medical device and biologics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion, as well as used as a therapeutic treatment for non-spinal and appendicular fractures.
Orthofix Medical Fundamentals Summary
|OFIX fundamental statistics|
Is OFIX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OFIX income statement (TTM)|
|Cost of Revenue||US$117.32m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.86|
|Net Profit Margin||-7.96%|
How did OFIX perform over the long term?See historical performance and comparison
Is Orthofix Medical undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: OFIX ($27.18) is trading above our estimate of fair value ($23.99)
Significantly Below Fair Value: OFIX is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: OFIX is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: OFIX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OFIX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OFIX is good value based on its PB Ratio (1.6x) compared to the US Medical Equipment industry average (2.5x).
How is Orthofix Medical forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: OFIX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: OFIX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: OFIX's is expected to become profitable in the next 3 years.
Revenue vs Market: OFIX's revenue (5.9% per year) is forecast to grow slower than the US market (8% per year).
High Growth Revenue: OFIX's revenue (5.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if OFIX's Return on Equity is forecast to be high in 3 years time
How has Orthofix Medical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OFIX is currently unprofitable.
Growing Profit Margin: OFIX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OFIX is unprofitable, and losses have increased over the past 5 years at a rate of 47.2% per year.
Accelerating Growth: Unable to compare OFIX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OFIX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.4%).
Return on Equity
High ROE: OFIX has a negative Return on Equity (-11.03%), as it is currently unprofitable.
How is Orthofix Medical's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: OFIX's short term assets ($255.1M) exceed its short term liabilities ($88.2M).
Long Term Liabilities: OFIX's short term assets ($255.1M) exceed its long term liabilities ($38.2M).
Debt to Equity History and Analysis
Debt Level: OFIX is debt free.
Reducing Debt: OFIX had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OFIX has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OFIX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Orthofix Medical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OFIX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OFIX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OFIX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OFIX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as OFIX has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jon Serbousek (60 yo)
Mr. Jon C. Serbousek had been the Chairman of the Board at Vesselon, Inc. since February 26, 2015 and served as its Director. He has been a Board Member at ArthroFree LLC. He has been President, Chief Exec...
CEO Compensation Analysis
Compensation vs Market: Jon's total compensation ($USD5.34M) is above average for companies of similar size in the US market ($USD2.65M).
Compensation vs Earnings: Jon's compensation has increased whilst the company is unprofitable.
Experienced Management: OFIX's management team is considered experienced (4.3 years average tenure).
Experienced Board: OFIX's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Orthofix Medical Inc.'s employee growth, exchange listings and data sources
- Name: Orthofix Medical Inc.
- Ticker: OFIX
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$539.603m
- Shares outstanding: 19.85m
- Website: https://www.orthofix.com
Number of Employees
- Orthofix Medical Inc.
- 3451 Plano Parkway
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.